Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus

Hiroshi Arima1
https://orcid.org/0000-0003-3746-1997

Timothy Cheetham2,3
https://orcid.org/0000-0003-3120-2513

Mirjam Christ-Crain4
https://orcid.org/0000-0002-6336-0965

Deborah L. Cooper5
https://orcid.org/0000-0003-4539-0906

Juliana B. Drummond6
https://orcid.org/0000-0002-9804-978X

Mark Gurnell7
https://orcid.org/0000-0001-5745-6832

Miles Levy8
https://orcid.org/0000-0001-7256-7880

Ann McCormack9,10,11
https://orcid.org/0000-0002-2859-5666

John D. Newell-Price12
https://orcid.org/0000-0002-0835-5493

Joseph G. Verbalis13
https://orcid.org/0000-0001-5745-6832

John Wass14
https://orcid.org/0000-0001-9145-4304

“ What’s in a name? That which we call a rose / By any other name would smell as sweet”
(Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare’s implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic meaning. Whilst this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rational for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology and endocrine pediatric societies now proposes changing the name of “diabetes insipidus” to “Arginine Vasopressin Deficiency (AVP-D)” for central etiologies, and “Arginine Vasopressin Resistance (AVP-R)” for nephrogenic etiologies This editorial provides both the historical context and the rational for this proposed name change.

REASONS FOR CHANGING A DISEASE NAME

Understanding of disease processes is a dynamic field, with rapidly evolving concepts of pathophysiology based on emerging molecular and genetic data. Consequently, newer understanding of pathophysiology is one of the major reasons for renaming diseases. In endocrinology, appreciation of hyperprolactinemia as the common pathophysiology underlying many different clinical situations causing galactorrhea and amenorrhea led to the effective abandonment of many previous eponymous names for these conditions such as Chiari-Frommel syndrome, Forbes-Albright syndrome, Ahumada-del Castillo syndrome, etc. (1). A second reason is based on historical discoveries that a previous eponymous name for a syndrome was inappropriately
attributed to an individual who was not the first or even the most significant person involved in the description of the syndrome (2). A third reason is later appreciation of medically unethical behaviors of individuals with diseases eponymously named for them, as characterized by the renaming of Reiter’s syndrome to “Reactive Arthritis” and Wegener’s granulomatosis to “Granulomatosis with Polyangiitis”, because of the association of the eponymous physicians with Nazi antihumanitarian crimes (3,4). The first three of these reasons for changing disease names make a strong case for detaching eponyms from disease processes whenever possible (5). However, endocrinologists would be loath to abandon the eponyms of Addison, Cushing, Hashimoto and others for their unique and seminal contributions to our understanding of endocrine disease processes. However, yet a fourth reason for renaming diseases is when traditional disease names lead to confusion between pathophysiologically different processes, leading to treatment errors and consequent adverse outcomes for patients. This latter reason represents the major impetus to change the name of diabetes insipidus at this time.

HISTORICAL CONTEXT

Before explaining the rational for the name change, it is instructive to review the historical context for the name of diabetes insipidus. The polyuria and polydipsia of diabetes was first described by Demetrius of Apameia (1st–2nd century BC), who used the term “diabetes”, meaning “passing water like a siphon” to describe the polyuria characteristic of this condition. Araetus of Cappadocia (81-138 A.D.) further defined the clinical characteristics of this disease (6). Although observations that the urine was sweet were alluded to in both Greek and Indian history, the first documented report of the sweet character of diabetic urine was published by the English physician Sir Thomas Willis in 1674 (“The Diabetes or Pissing Evil”). However, the differentiation between the saccharine urine of glucosuria and the non-saccharine urine of other forms of polyuria is attributed to the Scottish physician William Cullen, who appended the Latin word “mellitus” (sweet) to the Greek term diabetes to distinguish between these two types of polyuria (7). In 1794, Johann Peter Frank first introduced the term “diabetes insipidus” to differentiate these patients from those with diabetes mellitus (7). These terms persisted as valid clinical descriptions without known pathophysiology until the vasopressor and antidiuretic actions of posterior pituitary extracts were discovered in the late 19th and early 20th century, including use of posterior pituitary extracts to treat diabetes insipidus. In the mid-20th century, arginine vasopressin was synthesized and identified as the antidiuretic hormone, and the distinct central and nephrogenic etiologies of diabetes insipidus were recognized and characterized (8). Despite new knowledge of the underlying pathophysiology of the different etiologies of diabetes insipidus by the late 20th century, no attempts were made to rename diabetes insipidus according to the known causes of the disorder, namely deficiency of arginine vasopressin or resistance to the receptor-mediated actions of arginine vasopressin.

RATIONALE FOR CHANGING THE NAME OF DIABETES INSIPIDUS

There are multiple reasons to change the name of diabetes insipidus at this time. First and foremost, although the terms mellitus and insipidus do differentiate between the clinical characteristics of these two very different causes of polyuria, and clearly are not eponyms, the use of the common term “diabetes” in both has unfortunately led to confusion for both patients and their caretakers. This confusion with diabetes mellitus has been to the detriment of patients with diabetes insipidus when they are under the care of non-endocrine specialists. Some physicians and nurses do not appreciate the difference between these two very different disorders. In several patients with central diabetes insipidus, desmopressin treatment was withheld with serious adverse outcomes, including death (9). This has led to high profile litigation cases and coroners’ inquests involving the police, with wide media coverage. Subsequent to these unfortunate but avoidable cases, national safety alerts, surveys amongst endocrinologists, and a global task-force consisting of a wide range of senior clinicians involved with the care of patients with diabetes insipidus has led to a strong impetus to change the name of the condition. Second, patients with diabetes insipidus strongly support changing the name to eliminate “diabetes”. In a survey of >1,000 patients with central diabetes insipidus recently published in *The Lancet Diabetes & Endocrinology* (10), 85% preferred the name to be changed, mainly because of experiences with insufficient understanding of the disease by health professionals who confused this disorder with diabetes mellitus. Eighty-seven percent of patients
felt that this lack of knowledge and the resulting clinical confusion affected the management of their condition, e.g., repeated blood sugar measurements or prescription of medication for diabetes mellitus during hospitalization. Finally, we believe the names of medical disorders optimally should reflect the underlying pathophysiology, which in the case of diabetes insipidus is now well known to be deficient secretion and/or end-organ effects of the hormone arginine vasopressin (AVP). Hence, for all the above reasons, the working group proposes that the name diabetes insipidus should be changed to “Arginine Vasopressin Deficiency (AVP-D)” for central etiologies, and “Arginine Vasopressin Resistance (AVP-R)” for nephrogenic etiologies, and this proposal has been endorsed by the following societies represented by the working group members: Endocrine Society, European Society of Endocrinology, Pituitary Society, Society for Endocrinology, European Society for Paediatric Endocrinology, Endocrine Society of Australia, Brazilian Society of Endocrinology and Metabolism, and Japan Endocrine Society, and is under review at several other societies.

IMPLEMENTATION OF THE NAME CHANGE FOR DIABETES INSIPIDUS

In order to ease the transition in terms of on-line searches and avoid confusion in the literature, we propose that for several years we keep the previous name in parentheses. Therefore, we will begin using the terms AVP-Deficiency (cranial diabetes insipidus) and AVP-Resistance (nephrogenic diabetes insipidus) in manuscripts and chapters. Once the transition is complete, it is likely that the parenthetic term will be lost, albeit people can still use it if they wish. In addition, we have initiated a request to the ICD (International Statistical Classification of Diseases and Related Health Problems) Coordination and Maintenance Committee to have the ICD-11 coding changed to reflect the new names.

We fully recognize that changing a name for a long-standing disease is never easy. But just as the rheumatologists who proposed the name change of Granulomatosis with Polyangiitis (Wegener’s granulomatosis) (4), we hope our medical colleagues will recognize and accept the above rationale for making this change, both in the interest of scientific accuracy, but more so for the benefit and safety of our mutual patients with diabetes insipidus so that their disease and its treatment will no longer be confused with diabetes mellitus.

Acknowledgements: The Working Group for Renaming Diabetes Insipidus: Hiroshi Arima for the Japan Endocrine Society; Timothy Cheetham for the European Society for Paediatric Endocrinology; Mirjam Christ-Crain and Mark Gurnell for the European Society of Endocrinology; Deborah Cooper, Patient representative; Juliana Drummond for the Brazilian Society of Endocrinology and Metabolism; Miles Levy and Mark Gurnell for the Society for Endocrinology; Ann McCormack for the Endocrine Society of Australia; Joe Verbalis and John Newell-Price for the Endocrine Society; John Wass for the Pituitary Society.

Ethical approval: not applicable.

Authors contributions: all authors wrote and reviewed the position statement.

Funding: none.

Availability of data and materials: not applicable.

Disclosure: no potential conflict of interest relevant to this article was reported.

This article is CC BY and has been published in the following titles: Archives of Endocrinology and Metabolism, Clinical Endocrinology, Endocrine Connections, Endocrine Journal, European Journal of Endocrinology, Hormone Research in Pediatrics, Pituitary and The Journal of Clinical Endocrinology and Metabolism. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. A citation specific to one of the journals may be used when citing this article.

REFERENCES